Workflow
仁和药业(000650) - 2025 Q1 - 季度财报
000650RPC(000650)2025-04-28 08:05

Financial Performance - The company's revenue for Q1 2025 was ¥985,645,075.41, a decrease of 20.36% compared to ¥1,237,638,493.59 in the same period last year[5]. - Net profit attributable to shareholders was ¥164,307,562.31, down 7.33% from ¥177,296,535.93 year-on-year[5]. - The company's basic earnings per share decreased by 7.27% to ¥0.1174 from ¥0.1266 in the same period last year[5]. - Total operating revenue for the current period was ¥985,645,075.41, a decrease of 20.3% compared to ¥1,237,638,493.59 in the previous period[18]. - Net profit for the current period is CNY 196,735,645.41, a decrease of 6.4% from CNY 209,797,170.22 in the previous period[19]. - Total profit for the current period is CNY 248,377,205.20, down from CNY 264,397,235.57, reflecting a decline of 6.1%[19]. - Operating profit is CNY 248,844,587.57, compared to CNY 264,857,980.25 in the previous period, a decrease of 6.1%[19]. - The company reported a decrease in sales revenue from CNY 1,123,806,180.63 to CNY 853,461,972.41, a decline of 24.0%[20]. Cash Flow and Investments - The net cash flow from operating activities increased by 4.95% to ¥118,285,334.56 from ¥112,704,408.96 in the previous year[5]. - Cash and cash equivalents decreased to ¥522,924,601.84 from ¥2,328,656,330.79, a decline of 77.5%[15]. - Total cash inflow from investment activities is CNY 2,223,679,811.94, up from CNY 1,947,361,618.95, representing an increase of 14.1%[21]. - Cash outflow from investment activities totaled CNY 4,152,836,101.26, compared to CNY 3,545,601,855.15 in the previous period, an increase of 17.1%[21]. - Net cash flow from investment activities is CNY -1,929,156,289.32, worsening from CNY -1,598,240,236.20 in the previous period[21]. - Cash and cash equivalents at the end of the period stand at CNY 512,532,943.79, down from CNY 1,072,179,009.12, a decrease of 52.3%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,651,458,277.84, reflecting a 2.26% increase from ¥7,482,460,028.05 at the end of the previous year[5]. - Total liabilities decreased to ¥644,672,981.39 from ¥676,477,512.41, a reduction of 4.7%[16]. - The company’s total equity increased to ¥7,006,785,296.45 from ¥6,805,982,515.64, an increase of 2.9%[17]. - The company reported a significant increase in accounts receivable, rising to ¥556,363,683.20 from ¥365,723,160.00, an increase of 52.1%[15]. Expenses - Research and development expenses increased by 25.67% to ¥8,129,206.47, attributed to higher costs in technical development materials and evaluations[8]. - The company experienced a 46.61% reduction in selling expenses, which amounted to ¥93,047,616.52, mainly due to decreased wages and advertising costs[8]. - The company reported a 63.05% decrease in taxes paid, totaling ¥68,244,310.79, influenced by lower income and policy impacts[8]. - Dividend distribution to minority shareholders decreased by 87.42% to ¥2,160,774.19 compared to ¥17,183,054.46 last year[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 108,463[11]. - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 23.24% of shares, totaling 325,299,386 shares[11]. - The second-largest shareholder, Yang Xiao, holds 6.53% of shares, totaling 91,380,000 shares, with 68,535,000 shares pledged[11]. - The company did not have any preferred shareholders with voting rights restored during the reporting period[11]. - There were no significant changes in the top 10 shareholders' participation in margin trading activities[12]. - The company did not engage in stock repurchase activities during the reporting period, contrasting with the previous year[9].